Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Short Interest Update

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) was the target of a significant decline in short interest in the month of December. As of December 31st, there was short interest totalling 3,850,000 shares, a decline of 8.3% from the December 15th total of 4,200,000 shares. Based on an average trading volume of 606,000 shares, the days-to-cover ratio is presently 6.4 days. Currently, 6.7% of the shares of the company are short sold.

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,000 shares of the stock in a transaction on Friday, November 1st. The stock was sold at an average price of $110.84, for a total value of $110,840.00. Following the completion of the transaction, the chief executive officer now owns 428,976 shares in the company, valued at approximately $47,547,699.84. This represents a 0.23 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Neena M. Patil sold 3,700 shares of the business’s stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $123.41, for a total transaction of $456,617.00. Following the sale, the executive vice president now directly owns 33,048 shares in the company, valued at approximately $4,078,453.68. This represents a 10.07 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 8,253 shares of company stock worth $1,001,434 over the last ninety days. 4.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Large investors have recently modified their holdings of the stock. Rubric Capital Management LP purchased a new position in shares of Jazz Pharmaceuticals in the second quarter valued at $65,812,000. Pacer Advisors Inc. grew its stake in Jazz Pharmaceuticals by 40.7% during the 2nd quarter. Pacer Advisors Inc. now owns 1,820,913 shares of the specialty pharmaceutical company’s stock valued at $194,346,000 after purchasing an additional 527,187 shares in the last quarter. Baupost Group LLC MA grew its position in shares of Jazz Pharmaceuticals by 52.8% during the second quarter. Baupost Group LLC MA now owns 1,274,248 shares of the specialty pharmaceutical company’s stock worth $136,000,000 after buying an additional 440,552 shares in the last quarter. Millennium Management LLC grew its holdings in Jazz Pharmaceuticals by 1,808.4% during the 2nd quarter. Millennium Management LLC now owns 450,872 shares of the specialty pharmaceutical company’s stock worth $48,122,000 after acquiring an additional 427,246 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its position in shares of Jazz Pharmaceuticals by 48.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,222,198 shares of the specialty pharmaceutical company’s stock worth $130,447,000 after purchasing an additional 398,549 shares during the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Jazz Pharmaceuticals Stock Performance

NASDAQ:JAZZ opened at $121.18 on Monday. The firm’s fifty day simple moving average is $122.78 and its 200 day simple moving average is $114.75. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals has a twelve month low of $99.06 and a twelve month high of $134.17. The firm has a market capitalization of $7.33 billion, a price-to-earnings ratio of 17.07, a PEG ratio of 0.88 and a beta of 0.56.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on JAZZ. Piper Sandler reissued an “overweight” rating and issued a $163.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th. Morgan Stanley upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $140.00 to $175.00 in a research report on Thursday, December 12th. TD Cowen cut their price target on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a report on Thursday, November 7th. Needham & Company LLC restated a “buy” rating and set a $207.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, December 12th. Finally, HC Wainwright reiterated a “buy” rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a research report on Friday, November 22nd. Two analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Jazz Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $177.00.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.